Modification of biomedical polymers for prevention of fouling and clotting
US9078956B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jul 4, 2013 |
| Grant date | Jul 14, 2015 |
| Priority date | — |
| Expiry date | Jul 18, 2033 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2291/0426
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A surface-modified polymer is described, comprising a polymeric material and a self-assembling monolayer covalently bound thereto. The monolayer comprises monoethylene glycolated-OH (MEG-OH); 2-(3-trichlorosilyl-propyloxy)-ethyl-trifluoroacetate (7-OEG or MEG-TFA); 2,2,2-trifluoroethyl-13-trichlorosilyl-tridecanoate (TTTA); OEGylated TTTA (OEG-TTTA); S-(2-(2-(2-(3-trichlorosilyl-propyloxy)-ethoxy)-ethoxy)-ethyl)-benzenethiosulfonate (OEG-TUBTS); or a combination thereof. Methods are described for forming a surface-modified polymer by surface activation, such as with plasma. By utilizing the surface-modified polymer to make medical equipment or devices for contacting biological fluids, a reduction in surface fouling and thrombus formation can result. Advantageously, polymeric equipment or components so modified may have a reduction in unwanted chemical interactions leading to fouling or clotting. Short trichlorosilane surface modifiers allow films to be deposited onto poly(ethylene terephthalate), polycarbonate, polypropylene, polyvinyl chloride, polyurethane, and other polymers activated using plasma.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.